glp 1 agonist bone density GLP-1s and loss! Weight loss induced bone loss:

While there is no mention of NAION specifically, the label cautions that vision changes are a potential serious side effect and highlights concerns about diabetic retinopathy

Insurance rarely covers compounded medications but may cover brand-name alternatives (Zepbound or Wegovy) depending on your plan

TABLE 2 Overview of studies reporting on GLP-1 RAs and the risk of coronary events

The research findings Through a retrospective cohort study examining the electronic health records of more than 840,000 breast cancer patients who were diagnosed between 2006 and 2023, the results suggest there is a potential link between GLP-1 RAs and improved outcomes among breast cancer patients who are also obese or have type 2 diabetes

Allulose is a dietary sweetener with GRAS status as a food ingredient, not a pharmaceutical compound, and it does not directly bind to or activate GLP-1 receptors as prescription GLP-1 agonist medications do

In fact, it has been demonstrated that several molecules secreted by beta cells, such as insulin, zinc, and c-aminobutyric acid, inhibit the secretion of glucagon